高压氧治疗在儿童神经肿瘤中的应用:单中心经验
该单中心经验纳入7例(10-23岁,6例女性)儿童及年轻成人中枢神经系统肿瘤患者,因放射性坏死(n=5)或肿瘤相关水肿(n=2)接受高压氧治疗(3-60次)。4/7例临床改善,4例影像学改善,无长期不良事件。作者认为高压氧安全且耐受良好,但需临床试验确立其辅助治疗的安全性和有效性。
要点
- 7例儿童及年轻成人中枢神经系统肿瘤患者接受高压氧治疗,其中放射性坏死5例、肿瘤相关水肿2例。
- 高压氧治疗后4/7例临床改善,4例影像学改善,3例影像学疾病进展。
- 推测及活检证实的放射性坏死亚组5例中4例(80%)临床和影像学改善,无长期不良事件。
核心结论
- 高压氧治疗在儿童及年轻成人中枢神经系统肿瘤患者中安全且耐受良好。
- 超过半数患者观察到临床和影像学改善。
- 需要临床试验来确立高压氧作为儿童中枢神经系统肿瘤辅助治疗的安全性和有效性。
研究设计与样本
- 单中心经验,7例患者(年龄10-23岁,6例女性)接受高压氧治疗(3-60次),适应症为放射性坏死(n=5)或肿瘤相关水肿(n=2)。
- 肿瘤诊断包括低级别胶质瘤(n=4,其中2例神经纤维瘤病1型)、脑膜瘤(n=1)、髓母细胞瘤(n=1)和继发性高级别胶质瘤(n=1)。
- 既往治疗包括手术(n=4)、化疗(n=4)和放疗(n=5:4例局灶放疗,1例颅脊髓放疗);3例接受活检(1例证实放射性坏死,1例高级别胶质瘤,1例低级别胶质瘤)。
- 评估高压氧治疗后的临床和影像学变化。
主要发现
- 在接受过放疗的患者中,临床和影像学表现的中位时间为8.5个月(范围6个月至11年)。
- 高压氧治疗后(中位40次)7例中4例临床改善,2例症状稳定,1例恶化。
- 4例影像学改善,3例影像学疾病进展。
- 在推测及活检证实的放射性坏死亚组(n=5)中,5例中4例(80%)临床和影像学改善。
- 未发生与高压氧治疗相关的长期不良事件。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Hyperbaric oxygen therapy (HBOT) has been utilized as adjunctive treatment of CNS tumors and for radiation necrosis (RN) with reported success. The safety and efficacy in pediatric patients is less understood. METHODS: Seven patients (ages 10-23 years, six females) were treated with HBOT (3-60 sessions) for either RN (n = 5) or tumor-associated edema (n = 2). Tumor diagnosis included low-grade glioma (n = 4, two with neurofibromatosis type 1), meningioma (n = 1), medulloblastoma (n = 1) and secondary high grade glioma (n = 1). Prior therapies included: surgery (n = 4), chemotherapy (n = 4) and radiation (N = 5: four focal, one craniospinal). Three underwent biopsy: one confirming RN, one high-grade glioma, and one low-grade glioma. Patients were assessed for clinical and radiographic changes post HBOT. RESULTS: Median time to clinical and radiographic presentation was 8.5 months (range 6 months-11 years) in those who had prior radiation. Clinical improvement after HBOT (median: 40 sessions) was observed in four of seven patients. Symptoms were stable in two and worsened in one patient. Radiographic improvement was seen in four patients; three had radiographic disease progression. In the subgroup treated for presumed and biopsy-confirmed RN (n = 5), four of five (80%) had clinical and radiographic improvement. There were no long-term adverse events due to HBOT. CONCLUSIONS: HBOT is safe and well-tolerated in pediatric and young adult patients with CNS tumors. Clinical and radiographic improvements were observed in over half of patients. Clinical trials are needed to establish safety and efficacy of HBOT as adjunct therapy in pediatric CNS tumors.
引用
- Aghajan Y, Grover I, Gorsi H, et al. Use of hyperbaric oxygen therapy in pediatric neuro-oncology: a single institutional experience. J Neurooncol. 2018. PMID: 30426388. doi:10.1007/s11060-018-03021-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。